中信证券股份有限公司 关于金陵药业股份有限公司 向特定对象发行股票部分限售股份解除限售上市流通的核 查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为金陵药业 股份有限公司（以下简称"金陵药业"、"上市公司"或"公司"）2023 年度向特 定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》《深圳 证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》等相关规定，就公司向特定对象发行股票部分限售股份 解除限售上市流通的事项进行了核查，发表如下核查意见： 一、本次解除限售股份取得的基本情况及公司股本变动情况 本次发行股份为有限售条件流通股，公司控股股东新工集团所认购的股份自 发行结束之日起 18 个月内不得转让或上市交易，其他发行对象所认购的股份自 发行结束之日起 6 个月内不得转让或上市交易。具体发行情况如下： | 序号 | 发行对象名称 | 获配股数（股） | 限售期 | | --- | --- | --- | --- | | | | | （月） | | 1 | 南京新工投资集团有限责任公司 | 31,446,541 | 18 | ...

Core Viewpoint - The company has completed the repurchase and cancellation of 1,784,100 restricted stocks, which accounts for 0.29% of the total share capital prior to the repurchase, with a total repurchase amount of RMB 6,075,789 [2][3][18] Group 1: Repurchase Details - The repurchase involved 78 individuals and was executed due to the departure of one incentive object who no longer met the criteria of the incentive plan [2][9] - The repurchase price for the initially granted restricted stocks was adjusted from RMB 3.69 per share to RMB 3.29 per share, and for the reserved stocks from RMB 4.59 per share to RMB 4.29 per share [2][14] - After the cancellation, the company's total share capital changed from 623,708,628 shares to 621,924,528 shares [3][16] Group 2: Performance and Compliance - The company did not meet the performance assessment targets set for the incentive plan, leading to the repurchase of 155,100 shares from 61 incentive objects and 20,610 shares from 16 reserved incentive objects [10][11] - The repurchase was conducted in accordance with the regulations of the incentive plan and relevant laws, ensuring compliance with corporate governance [16][18] Group 3: Financial Impact - The repurchase and cancellation of restricted stocks are not expected to have a substantial impact on the company's financial status or operational results [18] - The company's equity structure remains compliant with listing requirements, and there will be no change in control for the major shareholders [18]

证券代码：000919 证券简称：金陵药业 公告编号：2025-066 金陵药业股份有限公司 关于限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司本次回购注销限制性股票 1,784,100 股，涉及 78 人，本 次回购注销限制性股票的数量占公司本次回购注销限制性股票前总 股本的 0.29%，首次授予部分限制性股票回购价格由 3.69 元/股调整 为 3.29 元/股，预留授予部分限制性股票回购价格由 4.59 元/股调整 为 4.29 元/股，回购资金总额为人民币 6,075,789 元。 1,784,100 股。近日，公司完成了上述限制性股票回购注销工作，现 将相关事项公告如下： 一、本次激励计划已履行的相关程序 1、2021 年 12 月 29 日，公司召开第八届董事会第十五次会议， 审议通过了《2021 年限制性股票激励计划（草案）》（以下简称"《激 励计划》"）及其摘要、《金陵药业股份有限公司 2021 年限制性股 票激励计划实施考核管理办法》《关于提请公司股东大会授权董事会 办理 2021 年限制性 ...

Group 1 - The high-pressure oxygen chamber concept declined by 1.90% as of the market close on September 22, ranking among the top declines in concept sectors, with companies like Hangzhou Oxygen, Innovative Medical, and China Railway Construction showing significant drops [1] - The high-pressure oxygen chamber sector experienced a net outflow of 238 million yuan from main funds today, with seven stocks seeing net outflows, and five stocks exceeding 10 million yuan in outflows. Innovative Medical led with a net outflow of 126 million yuan, followed by China Railway Construction and Hangzhou Oxygen [2] - The top stocks with net outflows in the high-pressure oxygen chamber sector included Innovative Medical (-4.18%), China Railway Construction (-2.36%), and Hangzhou Oxygen (-4.56%), with respective main fund outflows of 126.14 million yuan, 53.78 million yuan, and 21.64 million yuan [2] Group 2 - The concept sectors with the highest gains today included Tonghuashun Fruit Index (+5.17%), AI Mobile Phones (+4.06%), and Smart Speakers (+3.43%), while the high-pressure oxygen chamber sector was among the top decliners [2] - The main fund inflows were observed in stocks like Jinling Pharmaceutical, Weiao Co., and Dahu Co., with inflows of 2.58 million yuan, 1.16 million yuan, and 0.95 million yuan respectively [2]

Core Viewpoint - Jinling Pharmaceutical (000919) is experiencing a decline in stock price and facing challenges in its medical service segment, which now accounts for over 50% of its revenue, while industry classification remains inconsistent among different financial platforms [1][2]. Group 1: Stock Performance - As of September 10, 2025, Jinling Pharmaceutical's stock closed at 7.2 yuan, down 0.28% with a turnover rate of 1.15% [1]. - The trading volume was 67,900 shares, resulting in a transaction amount of 48.91 million yuan [1]. Group 2: Industry Classification - The company is classified differently by various financial institutions; it is categorized as part of the chemical pharmaceutical industry by Tonghuashun and as part of the traditional Chinese medicine industry by Dongfang Caifu, while the official classification by the China Securities Regulatory Commission lists it under the pharmaceutical manufacturing industry [2]. Group 3: Financial Performance and Comparison - Jinling Pharmaceutical's subsidiary, Suqian Hospital, has seen stagnant revenue and declining profits, contrasting with Xi'an Gaoxin Hospital under International Medical, which has experienced continuous growth in both revenue and profits [2]. Group 4: Capital Flow - On September 10, 2025, there was a net outflow of 4.702 million yuan from institutional investors and a net outflow of 2.1691 million yuan from speculative funds, while retail investors saw a net inflow of 6.8711 million yuan [3].

Core Viewpoint - Jinling Pharmaceutical experienced a stock price increase of 5.48% on August 7, reaching 7.51 CNY per share, with a total market capitalization of 4.684 billion CNY [1] Group 1: Company Overview - Jinling Pharmaceutical Co., Ltd. is located at No. 58, Xinguang Avenue, Nanjing Economic and Technological Development Zone, primarily engaged in the pharmaceutical and health care industries [1] - The pharmaceutical segment has production capabilities for nearly a hundred varieties of Chinese and Western medicines, while the health care segment controls three comprehensive hospitals and one integrated health care project company [1] - The company was listed on the Shenzhen Stock Exchange in 1999, issuing 80 million A-shares, with the controlling shareholder being Nanjing New Industry Investment Group Co., Ltd. [1] Group 2: Financial Performance - As of February 10, Jinling Pharmaceutical had 37,100 shareholders, with an average of 15,900 circulating shares per person [2] - For the period from January to September 2024, the company achieved a revenue of 2.22 billion CNY, representing a year-on-year growth of 5.51% [2] - The net profit attributable to shareholders was 71.3687 million CNY, showing a year-on-year decrease of 26.88% [2]

Core Viewpoint - Jinling Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of Orelagol tablets, which are intended for the treatment of moderate to severe pain associated with endometriosis [1][2]. Group 1: Clinical Trial Approval - The clinical trial application for Orelagol tablets was accepted on June 20, 2025, and has been approved to proceed with Phase III clinical research [2]. - The product is classified as a Class 3 chemical drug and is available in dosages of 150mg and 200mg [1][3]. - Orelagol is a GnRH antagonist used primarily for treating moderate to severe pain related to endometriosis [3]. Group 2: Regulatory Compliance - The application for the clinical trial meets the requirements set forth by the Drug Administration Law of the People's Republic of China [2]. - The approval signifies compliance with the relevant drug registration regulations [2]. Group 3: Product Information - Orelagol tablets are included in the second batch of encouraged generic drug lists in China [3].

Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]

Core Viewpoint - Jinling Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Olarogiv, marking a significant step in the development of this drug [2]. Group 1 - Jinling Pharmaceutical announced on September 3 that its subsidiary, Nanjing Jinling Pharmaceutical Factory, received a clinical trial application acceptance notice for Olarogiv on June 24, 2025 [2]. - The company has now obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing it to conduct Phase III clinical research for Olarogiv [2].

Core Viewpoint - Jinling Pharmaceutical has received approval for the Phase III clinical trial of Orelagol, a GnRH antagonist for treating moderate to severe pain associated with endometriosis, indicating a significant step in its product development pipeline [1] Group 1: Company Overview - Jinling Pharmaceutical's main business includes pharmaceutical and medical device manufacturing, as well as health care services [1] - The company’s product range covers cardiovascular, iron supplements, gastrointestinal medications, and oncology supportive drugs [1] - The company has a strong competitive advantage in the iron supplement market with its key product, Succinic Acid Iron Tablets [1] Group 2: Recent Financial Performance - In the first half of 2025, the company reported revenue of 1.6 billion yuan, a decrease of 6.6% year-on-year [1] - The net profit attributable to shareholders was 48.33 million yuan, down 14.08% year-on-year [1] - The net profit excluding non-recurring items was 35.51 million yuan, reflecting a decline of 21.6% year-on-year [1] Group 3: Business Strategy and Innovation - The company emphasizes the synergy between its pharmaceutical and health care platforms to support stable and high-quality development [2] - The pharmaceutical segment plays a crucial role, focusing on growth stabilization, cost reduction, structural adjustment, and capacity enhancement [2] - R&D investment increased by 20.51% year-on-year to 45.34 million yuan, with progress in product development and patent applications [2]